Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of erlotinib with or without bevacizumab in EGFR-mutated advanced NSCLC
jRCT2080221353Phase 2
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jan 2011
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in EGFR-mutated non-small cell lung cancer comparing Erlotinib monotherapy with Erlotinib plus bevacizumab (2 arms).
02
Drugs
erlotinibbevacizumab
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on jRCT2080221353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221353.